RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”), a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. Lee’s Pharm previously licensed RGN-259, RegeneRx’s sterile, preservative-free, topical eye drop developed for the treatment of ophthalmic indications such as dry eye syndrome (DES), neurotrophic keratitis (NK), and other persistent corneal disorders, in China, Taiwan, Macau, and Hong Kong.
Earlier this year Lee’s Pharm made a US$200,000 investment in RegeneRx as part of a convertible debt transaction, along with RegeneRx’s management and board of directors. Moreover, Lee’s Pharm recently completed a 60,000 square foot (5,500 square meters) production area and a 22,000 square foot (2,000 square meters) warehouse area, state-of-the-art ophthalmic manufacturing facility in China and has created a new subsidiary specializing in the development, manufacturing and marketing of ophthalmic topical drugs.
Dry eye syndrome is a rapidly-growing problem in China due to the large urban populations, poor air quality, and the over-use of electronic monitors. DES is also associated with diabetes; the diabetes epidemic in China is thought to be the highest population of diabetes in the world. In 2016, China had the world’s highest number of total prevalent cases of DES with 194 million followed by the U.S. with 23 million, according to GlobalData (2018).
“We are pleased Lee’s Pharm is accelerating its effort to develop RGN-259 and recognize that it could have a significant impact on the treatment of numerous ophthalmic disorders in China. The Chinese market is the world’s largest and growing rapidly according to most industry reports. With its new manufacturing facility, Lee’s Pharm is now in a position to effectively develop and commercialize RGN-259. We look forward to helping in every way we can with this effort,” stated J.J. Finkelstein, RegeneRx’s President and Chief Executive Officer.
